PLX - Protalix BioTherapeutics, Inc.

2.9
0.020   0.690%

Share volume: 632,431
Last Updated: 03-10-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$2.88
0.02
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
29%
Profitability 32%
Dept financing 25%
Liquidity 27%
Performance 26%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
10.69%
1 Month
-0.68%
3 Months
58.47%
6 Months
66.67%
1 Year
28.32%
2 Year
101.39%
Key data
Stock price
$2.90
P/E Ratio 
32.82
DAY RANGE
$2.87 - $2.98
EPS 
$0.07
52 WEEK RANGE
$1.32 - $3.19
52 WEEK CHANGE
$29.46
MARKET CAP 
177.005 M
YIELD 
N/A
SHARES OUTSTANDING 
80.421 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-09-2025
BETA 
-0.50
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,167,462
AVERAGE 30 VOLUME 
$1,470,316
Company detail
CEO: Dror Bashan
Region: US
Website: protalix.com
Employees: 200
IPO year: 1998
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Protalix BioTherapeutics, Inc. focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials.

Recent news